Rikshospitalet-Oslo University Hospital, Lipid Clinic, Medical Department, 0027 Oslo, Norway.
Expert Opin Investig Drugs. 2009 Sep;18(9):1405-11. doi: 10.1517/13543780903164205.
Taspoglutide (R1583/BIM51077) is a new anti diabetic drug from Hoffmann-La Roche. The compound is to be administered as a subcutaneous injection once weekly and is also effective given bi-weekly. It is a long acting 10% formulation of (Aib 8-35) human glucagon-like polypeptide-1 (7 - 36 amides) with 93% homology with the native polypeptide. It activates the glucagon-like polypeptide-1 receptor. Phase III trials are currently in process.
To provide a critical review of taspoglutide based on available published data.
Information provided from the search on Internet has been reviewed. A clinical interpretation is given on a background of practical experience as an investigator in a clinical trial with taspoglutide.
Search on PubMed, EMBASE and Google gave hits on six clinical studies investigating taspoglutide of which the largest accounted for > 50% of the total study population. In addition, some animal studies were identified. Significant improvement on glucose control as well as several metabolic parameters has been shown with taspoglutide.
Data from the clinical trials are interpreted in a medical context. The prospects of taspoglutide in the treatment of diabetes type 2 and metabolic syndrome are discussed.
Taspoglutide is a new activator of the glucagon-like polypeptide-1 receptor. It is effective when injected once weekly and less effective when injected bi-weekly. In addition to its anti diabetic properties, taspoglutide has favorable effects on body weight and significantly reduces three of five diagnostic criteria for metabolic syndrome, namely glucose, waist circumference and fasting triglyceride.
Taspoglutide（R1583/BIM51077）是罗氏制药的一种新型抗糖尿病药物。该化合物通过皮下注射给药，每周一次，每两周一次也同样有效。它是一种长效 10%的（Aib8-35）人胰高血糖素样肽-1（7-36 酰胺）制剂，与天然多肽有 93%的同源性。它能激活胰高血糖素样肽-1 受体。目前正在进行 III 期临床试验。
基于现有已发表的数据，对 taspoglutide 进行批判性评价。
检索互联网上提供的信息，并结合作为 taspoglutide 临床试验研究者的实际经验进行临床解读。
在 PubMed、EMBASE 和 Google 上搜索到 6 项研究 taspoglutide 的临床试验，其中最大的一项研究占总研究人群的 50%以上。此外，还确定了一些动物研究。研究表明，taspoglutide 能显著改善血糖控制和多种代谢参数。
对临床试验数据进行医学背景下的解读。讨论了 taspoglutide 在治疗 2 型糖尿病和代谢综合征方面的前景。
Taspoglutide 是一种新型胰高血糖素样肽-1 受体激动剂。每周注射一次有效，每两周注射一次效果较差。除了抗糖尿病作用外，taspoglutide 还对体重有有利影响，并显著降低了代谢综合征的五个诊断标准中的三个，即血糖、腰围和空腹甘油三酯。
